Journal of Managed Care & Specialty Pharmacy

Article	Citations
Specialty drug use for autoimmune conditions varies by race and wage among employees with employer-sponsored health insurance	28
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis	27
International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments	25
What is needed to sustain comprehensive medication management? One health plan’s perspectives	22
Real-world calibration and transportability of the Disease Recovery Evaluation and Modification (DREaM) randomized clinical trial in adult Medicaid beneficiaries with recent-onset schizophrenia	19
Effect of relaxing hepatitis C treatment restrictions on direct-acting antiviral use in a Medicaid program: an interrupted time series analysis	17
Correction	16
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data	16
Medicare drug price negotiation: The complexities of selecting therapeutic alternatives for estimating comparative effectiveness	15
Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies	14
Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy	12
Pediatric-onset rare disease therapy pipeline yields hope for some and gaps for many: 10-year projection of approvals, treated patients, and list price revenues	11
The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder	11
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis	11
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	11
Payer perceptions of the use of real-world evidence in oncology-based decision making	10
Real-world evidence: A new era is upon us	10
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	10
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States	10
Cost-effectiveness of gilteritinib for relapsed/refractory FLT3mut+ acute myeloid leukemia	10
Evaluating patient-reported adherence and outcomes in specialty disease states: A dual-site initiative	9
Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B	9
Pharmacist impact on evidence-based prescribing of diabetes medications in patients with clinical atherosclerotic cardiovascular disease	9
Trends in Medicaid spending on inhalers in the United States, 2012-2018	9
Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria	9

Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol	9
Real-world primary nonadherence to antiobesity medications	9
Emerging trends in therapeutics and diagnostics: Perspectives on the 2024 AMCP Foundation Survey	9
Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study	8
Navigating the landscape of food allergies: Insights and perspectives from the AMCP Market Insights Program	8
Poster Abstracts - Academy of Managed Care Pharmacy 2024	8
Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions	8
Considerations for US coverage and reimbursement: Which digital health products to evaluate? Findings from a modified Delphi study	8
Introducing the Managed Care Pharmacy Primer Series	7
ICER report on Alzheimer’s disease: implications from a patient perspective	7
Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non–small cell lung cancer	7
Social determinants of health and adult influenza vaccination: a nationwide claims analysis	7
The cost-effectiveness of pharmacist-physician collaborative care models vs usual care on time in target systolic blood pressure range in patients with hypertension: a payer perspective	7
Association of dyskalemias with short-term health care utilization in patients with advanced CKD	7
Copay assistance use and prescription abandonment across race, ethnicity, or household income levels for select rheumatoid arthritis and oral oncolytic medicines	7
AMCP Format for Formulary Submissions 5.0	7
The patient’s medication access journey: a conceptual framework focused beyond adherence	6
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	6
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States	6
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia	6
Cost and clinical impact of a nonmedical DPP-4 inhibitor switch in patients with diabetes	6
Addressing gaps to strengthen patient-centricity in formulary decision-making: An example applied to Colorado’s prescription drug affordability board implementation	6
Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system	6
Place of care and costs associated with acute episodes and remission in schizophrenia	6
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population	6
Economic burden related to fistulas or strictures among commercially insured patients with Crohn’s disease in the United States	6
From access to equity: The devil is in “Z” details	6
Burden of chronic corticosteroid use among patients with ulcerative colitis initiated on targeted treatment or conventional therapy in the United States	6
Laboratory monitoring to reduce adverse drug-related events: a mixed methods study	6
Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs	6
Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States	6
Medical costs and associated racial/ethnic and sex disparities in erythropoiesis-stimulating agent use: anemia management under the Medicare reimbursement policy	6
Antidepressant adherence using group-based trajectory modeling among postpartum women with Texas Medicaid	6
Correction	6
Risk of asthma exacerbation associated with opioid and nonopioid analgesic use in children with current asthma	5
Using a patient-centered value assessment to optimize fair prices for Inflation Reduction Act’s Medicare Drug Price Negotiation Program	5
Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs	5
Adherence and persistence in patients with rheumatoid arthritis at an integrated health system specialty pharmacy	5
Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis	5
Emerging trends in pharmaceutical payment models: Perspectives on the 2024 AMCP Foundation Survey	5
Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States	5
Cost sharing in managed care and the ethical question of business purpose	5
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder	5
Poster Abstracts - Academy of Managed Care Pharmacy 2025	5
Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review	5
A dynamic analysis of medication adherence	5
Polypharmacy in US Medicare beneficiaries with antineutrophil cytoplasmic antibody vasculitis	5
The use of short-acting bronchodilators and cost burden of asthma across Global Initiative for Asthma–based severity levels: Insights from a large US commercial and managed Medicaid population	5
Nonfederal average manufacturer price to estimate savings generated by minimum discounts under the Inflation Reduction Act	5
Impact of mental health in persons living with rare disease: Findings from the AMCP Market Insights Program	5

Resmetirom for nonalcoholic steatohepatitis	5
When are breakthrough therapies cost-effective?	5
The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review	4
Payer perceptions on the use of patient-reported outcomes in oncology decision making	4
The economic burden of Parkinson disease among Medicare beneficiaries	4
Oral treatments for outpatient COVID-19: Effectiveness and value	4
The effectiveness and value of aducanumab for Alzheimer’s disease	4
Need for payer-provider partnerships in addressing social determinants of health	4
Health care resource utilization and costs in patients with painful diabetic neuropathy treated with 10 kHz spinal cord stimulation therapy	4
Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis	4
Patient-reported disability progression outcomes among patients with multiple sclerosis: Results of an outcomes-based agreement	4
The impact of a statewide insulin copay cap policy for insured patients with diabetes in Utah	4
Imetelstat for anemia in lower-risk myelodysplastic syndromes: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum	4
Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma	4
Financial impact of integrated specialty pharmacy efforts to avoid oral anticancer medication waste	4
Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: Effectiveness and value	4
Emerging trends in public policy: Perspectives on the 2024 AMCP Foundation Survey	4
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	4
Examining US commercial health plans’ use of The Institute for Clinical and Economic Review’s reports in specialty drug coverage decisions	4
Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it	4
Correction	4
Descriptive, real-world treatment patterns, resource use, and total cost of care among eculizumab- and ravulizumab-treated members with paroxysmal nocturnal hemoglobinuria	4
Pharmacists as clinical care partners: How a pharmacist-led intervention is associated with improved medication adherence in older adults with common chronic conditions	4
Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies	4
Insights into insurance coverage for digital therapeutics: A qualitative study of US payer perspectives	4
AMCP Partnership Forum: Biosimilars—policy, practice, and postmarketing surveillance to support treatment and coverage decisions	4
Health care resource utilization and costs among patients with spasticity or cervical dystonia	4
Health care costs and resource utilization among patients with myasthenia gravis in the United States	4
Persistence and other treatment patterns among bio-experienced patients with Crohn’s disease initiated on ustekinumab or adalimumab	4
Effect of the population health inpatient Medicare Advantage pharmacist intervention on hospital readmissions: A quasi-experimental controlled study	4
Real-world switching and discontinuation outcomes of infliximab biosimilars in patients with rheumatoid arthritis: A scoping review	4
Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States	4
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States	4
Burden of hospitalization for heart failure in the United States: a systematic literature review	4
AMCP Partnership Forum: Racial health disparities—a closer look at benefit design	4
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders	4
Formulary tiers, medication cost sharing, and transparency in bronze and silver qualified health plans in 2014 vs 2018	3
Marginal health care expenditures and health-related quality of life burden in patients with migraine	3
The effects of patient out-of-pocket costs for insulin on medication adherence and health care utilization in patients with commercial insurance; 2007-2018	3
Unlocking the potential of digital therapeutics: The need for consistent and granular inclusion in drug compendia for managed care	3
The cost impact of disease progression to metastatic castration-sensitive prostate cancer	3
Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C	3
Dose escalation of biologics in biologic-naive patients with Crohn’s disease: Outcomes from the ODESSA-CD study	3
Utilization and patient characteristics for the trastuzumab reference and biosimilars, and other human epidermal growth factor receptor 2 inhibitors in the United States	3
A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective	3
The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with RET alterations	3
The high cost burden of third- to fifth-line treatments for multiple myeloma: unsustainable and unaffordable	3
Economic burden of interstitial lung disease in a commercially insured population with Sjögren syndrome in the United States	3
Corrections	3
Factors associated with primary nonadherence to newly initiated direct oral anticoagulants in patients with nonvalvular atrial fibrillation	3
A comparison of clinical, utilization, and cost outcomes between oral treatments for multiple sclerosis	3
Comparison of a second TNFi vs other biologic or targeted synthetic DMARD following an initial TNFi	3
Perceived appropriateness of medication adherence incentives	3
Pharmacist vs physician management of e-visit requests for COVID-19 medication: A randomized clinical trial	3
Patient liability, treatment adherence, and treatment persistence associated with state bans of copay accumulator adjustment programs	3
Clinical and economic characterization of mild, moderate, and severe systemic lupus erythematosus: Real-world observation across payer channels in the United States	3
Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schi	3
Impact of social determinants of health on esketamine nasal spray initiation among patients with treatment-resistant depression in the United States	3
Assessing variation in US payer coverage of anti–vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema	3
Atidarsagene autotemcel for metachromatic leukodystrophy	3
Application of a diazepam milligram equivalency algorithm to assess benzodiazepine dose intensity in Rhode Island in 2018	3
A primer on copay accumulators, copay maximizers, and alternative funding programs	3
Marginal health care expenditures for melanoma care in the United States	3
Descriptive study of the economic burden among patients with type 2 diabetes mellitus, chronic kidney disease, and chronic kidney disease and type 2 diabetes mellitus in a large US commercially insure	3
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study	3
Limited utility of price transparency data for drugs	3
Validation of EHR medication fill data obtained through electronic linkage with pharmacies	3
Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor–positive/human epidermal growth factor receptor 2–negative early breast cance	3
An online survey among US patients with immune-mediated conditions: Attitudes about biosimilars	3
Clinical and economic burden of neovascular age-related macular degeneration by disease status: a US claims-based analysis	3
Characterizing health plan evidence review practices	3
Dynamic changes in medication burden leading to fall and hospital readmissions in older adults: Toward a strategy for improving risk and managing costs	3
HIV preexposure prophylaxis treatment patterns in a national health plan population	3
Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective	3
Inhaled treprostinil vs iloprost: Comparison of adherence, persistence, and health care resource utilization in patients with pulmonary arterial hypertension	3
Predictors of flare-related inpatient or emergency department stay in systemic lupus erythematosus: A real-world analysis of Medicaid claims in the United States	3
Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste	3
Building health plan–pharmacist provider partnerships to optimize medication outcomes	3
Pharmacoequity measurement framework: A tool to reduce health disparities	3
Associations between pharmacy choice and influenza vaccination: Mail order vs community pharmacy users	3

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis	3
Poster Abstracts - Academy of Managed Care Pharmacy 2022	3
Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non–small cell lung cancer	2
Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from t	2
Changes in blood pressure, medication adherence, and cardiovascular-related health care use associated with the 2018 angiotensin receptor blocker recalls and drug shortages among patients with hyperte	2
Within-trial economic analysis of resource use from COMET-ICE: A phase 3 clinical trial evaluating sotrovimab for the treatment of patients with COVID-19 at high risk of progression	2
Cancer history, insurance coverage, and cost-related medication nonadherence in Medicare beneficiaries, 2013-2018	2
Comparison of oral anticoagulation use and adherence among Medicare beneficiaries enrolled in stand-alone prescription drug plans vs Medicare Advantage prescription drug plans	2
Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment	2
Perceptions of prior authorization by use of electronic prior authorization software: A survey of providers in the United States	2
Health care resource utilization and costs among individuals with vs without Huntington disease in a US population	2
Impact of pharmacist alternative therapy interventions in a pediatric Medicaid population	2
Burden of lipoprotein(a) for patients with atherosclerotic cardiovascular disease: A retrospective analysis from the United States	2
Comparing costs and health care resource utilization between nmHSPC and mHSPC patients: a retrospective claims analysis	2
Emerging trends in pharmacy operations: Perspectives on the 2024 AMCP Foundation Survey	2
Concentration of spending and share of specialty drug spending in Medicare Part D over a 10-year period	2
Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease	2
Objective medication adherence and persistence in people with multiple sclerosis: a systematic review, meta-analysis, and meta-regression	2
The impact of opioid prescribing report cards in Medicaid	2
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy	2
Evolving oncology care management trends in the United States: A survey among health care decision makers	2
Optimizing the management of inherited blood disorders in a changing market: Findings from the AMCP Market Insights Program	2
Health care resource utilization and costs associated with psychiatric comorbidities in adult patients with attention-deficit/hyperactivity disorder	2
Manufacturer-sponsored drug coupon use and drug-switching behavior among patients with type 2 diabetes	2
Health care resource utilization and costs in patients receiving long-acting injectable vs oral antipsychotics: A comparative analysis from the Disease Recovery Evaluation and Modification (DREaM) stu	2
Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation	2
Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis	2
The effects of oral anticancer parity laws on out-of-pocket spending and adherence among commercially insured patients with chronic myeloid leukemia	2
Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved popul	2
Schizophrenia population health management: perspectives of and lessons learned from population health decision makers	2
Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States	2
Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure	2
Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorder	2
Real-world effectiveness of omadacycline and impact of unapproved omadacycline prescription claims among adult outpatients with community-acquired bacterial pneumonia or acute bacterial skin and skin	2
Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective	2
The impact of biosimilar insulins on the diabetes landscape	2
The role of integrated medical and prescription drug plans in addressing racial and ethnic disparities in medication adherence	2
Procurement and use of social determinants of health data among key health care stakeholders	2
A harm reduction model to assess the impact of new treatments for pain over standard of care among patients with osteoarthritis	2
Few new drugs deserve expedited regulatory treatment	2
Short-term cost-effectiveness of oral semaglutide for the treatment of type 2 diabetes mellitus in the United States	2
The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia	2
Costs associated with the administration of erythropoiesis-stimulating agents for the treatment of anemia in patients with non-dialysis-dependent chronic kidney disease: a US societal perspective	2
Pharmacist-managed multistep order transmittal for electronic specialty prescriptions reduces represcribing burden in ambulatory clinics: A retrospective cohort pilot study	2
Comorbid depression and anxiety and their association with health care resource utilization among individuals with type 1 diabetes in the United States	2
Correction	2
Emerging trends in managed care pharmacy: A mixed-method study	2
Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor	2
“It’s Time to Represent”: shifting the paradigm to improve the quality of inputs into value assessment frameworks	2
Use of prescriber requirements among US commercial health plans	2
Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States	2
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults	2
A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B	2
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases	2
Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analys	2
Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model	2
Individual and social determinants of adherence to sodium-glucose cotransporter 2 inhibitor therapy: A trajectory analysis	2
Burden of illness in progressive fibrosing interstitial lung disease	2
Correction	2
A summit on amplifying voices of patients, caregivers, and people with disabilities in Inflation Reduction Act drug price negotiations	2
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective	2
Determining health care cost drivers in older Hodgkin lymphoma survivors using interpretable machine learning methods	2
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US	2
Health care resource utilization and costs associated with atrial fibrillation and rural-urban disparities	2
The effect of unobserved preferences and race on vaccination hesitancy for COVID-19 vaccines: implications for health disparities	2
Development of stakeholder-informed recommendations for inclusion of family spillover effects in health technology assessment	2
Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: Development of a predictive algorithm using claims data	2
Area deprivation index impact on type 2 diabetes outcomes in a regional health plan	2
Does the diabetes health plan have a differential impact on medication adherence among beneficiaries with fewer financial resources?	2
Anticipated efficiencies, real costs: Medicaid managed care organizations and the pharmacy benefit	2
The time is now: Addressing health inequities in the workforce	2
Valuing diversity in value assessment: introducing the PhRMA Foundation Health Disparities Challenge Award	2
Descriptive study of the real-world, long-term cost estimates and duration of use for hormonal and nonhormonal intrauterine devices using US commercial insurance claims	2
Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018	2
Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system	2
Impact of a human papillomavirus vaccination clinical program in a commercially insured population	2
Overcoming barriers to biosimilar adoption: real-world perspectives from a national payer and provider initiative	2
Analyzing the use and impact of elexacaftor/tezacaftor/ivacaftor on total cost of care and other health care resource utilization in a commercially insured population	2
Best practices and rationale for expanding Medicaid access to continuous glucose monitoring	2
Telephone-based social health screening by pharmacists in the nonadherent Medicare population	2
Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims	1
KarXT for schizophrenia–effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council	1
Racial and social inequities in medication use: A review of articles responding to the Journal of Managed Care + Specialty Pharmacy’s Call to Action	1
Evaluation of financial outcomes under a value-based payment program for community pharmacies	1
Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression	1
A primer on formulary structures and strategies	1
Direct-acting antiviral retreatment patterns for hepatitis C	1
Real-world treatment and health care utilization among patients with Duchenne muscular dystrophy by race and ethnicity in a Medicaid population	1
Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors	1
The evolution of payer management of oncology drugs in the United States between 2017 and 2022	1
Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes	1
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma	1
Advancing a managed care pharmacy research agenda: Generating real-world evidence to support US Food and Drug Administration Accelerated Approvals and improving benefit design to address health inequi	1
Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration–expedited programs	1
Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non–small cell lung cancer	1